{
  "colNames":[
    {"field":"BASELINE","headerName":"BASELINE"},
    {"field":"PROJECT_DESC_FINAL","headerName":"PROJECT_DESC_FINAL"},
    {"field":"FY","headerName":"FY"},
    {"field":"FTE","headerName":"FTE"},
    {"field":"TOTAL_FTE","headerName":"TOTAL_FTE"},
    {"field":"PERCENTAGE","headerName":"PERCENTAGE"}
  ],
  "colNamesArray":["BASELINE","PROJECT_DESC_FINAL","FY","FTE","TOTAL_FTE","PERCENTAGE"],
  "data":[
    {"BASELINE":"Apr 19","FTE":"0.25079337904761901640","FY":"2019","PERCENTAGE":"0.000089793233813118416562","PROJECT_DESC_FINAL":"","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"0.31371086574806993600","FY":"2020","PERCENTAGE":"0.000122099785943291300058","PROJECT_DESC_FINAL":"","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"5.05354169587703847320","FY":"2019","PERCENTAGE":"0.001809353392044972000264","PROJECT_DESC_FINAL":"1R/GCGR","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"0.05725388601036269500","FY":"2020","PERCENTAGE":"0.000022283854305195976989","PROJECT_DESC_FINAL":"1R/GCGR","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"4.58348473592634525260","FY":"2019","PERCENTAGE":"0.001641055749297704467225","PROJECT_DESC_FINAL":"ABCA4 GENE THERAPY","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"2.22248145692754814827","FY":"2020","PERCENTAGE":"0.000865014699145649041236","PROJECT_DESC_FINAL":"ABCA4 GENE THERAPY","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"6.56468364019804340790","FY":"2019","PERCENTAGE":"0.002350397667003532097099","PROJECT_DESC_FINAL":"ALPROLIX","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"2.97291449803843191077","FY":"2020","PERCENTAGE":"0.001157091651806877527005","PROJECT_DESC_FINAL":"ALPROLIX","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"15.03172446645317712510","FY":"2019","PERCENTAGE":"0.005381909023101928059707","PROJECT_DESC_FINAL":"ALX0081 - Anti vWF nanobody - Caplacizumab ","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"12.95718214415022716828","FY":"2020","PERCENTAGE":"0.005043080552713410128416","PROJECT_DESC_FINAL":"ALX0081 - Anti vWF nanobody - Caplacizumab ","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"8.73297273736163582090","FY":"2019","PERCENTAGE":"0.003126724739972543605064","PROJECT_DESC_FINAL":"Anti-CD38 mAB Fc engineered","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"11.15973302039314585160","FY":"2020","PERCENTAGE":"0.004343493202650300654845","PROJECT_DESC_FINAL":"Anti-CD38 mAB Fc engineered","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"30.21715045977285826488","FY":"2019","PERCENTAGE":"0.010818848833666298599062","PROJECT_DESC_FINAL":"AUBAGIO","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"25.13256563519660217946","FY":"2020","PERCENTAGE":"0.009781876304939889440145","PROJECT_DESC_FINAL":"AUBAGIO","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"1.26567164827558097010","FY":"2019","PERCENTAGE":"0.000453156900217311282881","PROJECT_DESC_FINAL":"AVE0005 - VEGF TRAP angiogenic inh. - aflibercept - ZALTRAP","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"0.14857142857142856000","FY":"2020","PERCENTAGE":"0.000057825665625584177149","PROJECT_DESC_FINAL":"AVE0005 - VEGF TRAP angiogenic inh. - aflibercept - ZALTRAP","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"0.21190476190476190700","FY":"2019","PERCENTAGE":"0.000075869681664182348974","PROJECT_DESC_FINAL":"BIVV002 - rFIX Fc-XTEN","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"0.28392857142857143700","FY":"2020","PERCENTAGE":"0.000110508183106585158016","PROJECT_DESC_FINAL":"BIVV002 - rFIX Fc-XTEN","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"3.78914115384043381866","FY":"2019","PERCENTAGE":"0.001356651594510798306652","PROJECT_DESC_FINAL":"BIVV003 - Gene editing Technology","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"4.00267947498685543255","FY":"2020","PERCENTAGE":"0.001557887725470049246557","PROJECT_DESC_FINAL":"BIVV003 - Gene editing Technology","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"5.49818695392159271841","FY":"2019","PERCENTAGE":"0.001968552712900679745258","PROJECT_DESC_FINAL":"BIVV020 - Complement C1s Inhibitor","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"7.21640184123412540750","FY":"2020","PERCENTAGE":"0.002808704499266713400158","PROJECT_DESC_FINAL":"BIVV020 - Complement C1s Inhibitor","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"54.31469076285408804981","FY":"2019","PERCENTAGE":"0.019446652641615988400318","PROJECT_DESC_FINAL":"BTK INHIBITOR","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"26.20290487664191819590","FY":"2020","PERCENTAGE":"0.010198464337220954639414","PROJECT_DESC_FINAL":"BTK INHIBITOR","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"11.35591241429932300500","FY":"2019","PERCENTAGE":"0.004065833406171628540537","PROJECT_DESC_FINAL":"CD3/CD123 ANTIBODIES","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"18.44073031826924962690","FY":"2020","PERCENTAGE":"0.007177338977817953221718","PROJECT_DESC_FINAL":"CD3/CD123 ANTIBODIES","TOTAL_FTE":"2569.29906407675068066974"},
    {"BASELINE":"Apr 19","FTE":"6.47401889702509554558","FY":"2019","PERCENTAGE":"0.002317936361552605246003","PROJECT_DESC_FINAL":"CD40L MAB","TOTAL_FTE":"2793.00976696730963280149"},
    {"BASELINE":"Apr 19","FTE":"17.65888014792978127093","FY":"2020","PERCENTAGE":"0.006873034126245363869200","PROJECT_DESC_FINAL":"CD40L MAB","TOTAL_FTE":"2569.29906407675068066974"}
  ]
}
